Dyne Therapeutics Inc
DYNHealthcare|Biotechnology|USA
$23.43
-0.84 (-3.48%)
Tangible Book
$5.24
Earnings Power
$4.45
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07486934 Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 | Myotonic Dystrophy Type 1 (DM1), DM1 | P3 | Recruiting | 150 | RCT, Double-blind | zeleciment basivarsen (DYNE-101), Placebo |
| NCT07608432 Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) | Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne | P3 | Recruiting | 90 | RCT, Double-blind | Zeleciment Rostudirsen (DYNE-251), Placebo |
| NCT05481879 Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | Myotonic Dystrophy Type 1 (DM1) | P1P2 | Recruiting | 116 | RCT, Double-blind | DYNE-101, Placebo |
| NCT05524883 Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | Duchenne Muscular Dystrophy (DMD) | P1P2 | Active | 86 | RCT, Double-blind | DYNE-251, Placebo |
| NCT04635891 Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) | FSHD | Recruiting | 450 | — | — | |
| NCT03458832 Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD | Facioscapulohumeral Muscular Dystrophy | Active | 324 | — | — |